April 11, 2026 06:46 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Amit Shah promises UCC, ₹3,000 aid per month for women and youth in BJP’s Bengal manifesto | Nitish Kumar takes Rajya Sabha oath; power shift looms in Bihar | Sting video fallout: AIMIM snaps electoral ties with Humayun Kabir in Bengal | Israel says Hezbollah chief’s nephew-cum-secretary killed in Beirut strikes last night | Modi slams TMC on trade, fisheries at Haldia; vows 7th pay commission for govt employees | ‘US military will remain in and around Iran’: Trump amid fragile ceasefire | BJP eyes Assam hattrick, Puducherry comeback; LDF faces Kerala test | Israel claims Hezbollah chief's nephew killed in Beirut strikes last night | Jaishankar’s high-stakes diplomatic tour: EAM to visit UAE this week, first visit amid Middle East conflict | Passport row: Barricades outside Pawan Khera’s Hyderabad house after Himanta Biswa Sarma's warning
Johnson&Johnson Vaccine

Kolkata's Peerless Hospital commences Johnson & Johnson vaccine's clinical trial

| @indiablooms | May 08, 2021, at 03:50 am

Kolkata/IBNS: Kolkata's Peerless Hospital has been selected as the only trial venue in the East for Johnson & Johnson for their single-dose vaccine which is currently being used under emergency authorization.

In a statement Dr Subhrajyoti Bhowmick, Clinical trial specialist and clinical Pharmacologist and Director, Clinical Research Peerless Hospital, Kolkata said, " We shall be recruiting 100 participants at this site, six such sites have been selected for this trial of this unique single dose vaccine."

"I am confident we shall get enough volunteers for the clinical trial as vaccine supply is short and the supply of Covishield and Covaxine is less than the huge demand. The ratio shall be 3:1 as three volunteers will get a vaccine while one person shall get a placebo. We are now awaiting the ethics committee approval on which we shall embark on the clinical trials," concluded Bhowmick.

Earlier, Sputnik V, developed by Gamaleya Research Institute of Epidemiology and Microbiology in Russia, has been approved for use in India.

Five million doses of Sputnik V are expected to arrive in India by June.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.